New drug daraxonrasib doubles pancreatic cancer survival rates

lesechos.fr (French)

A new drug, daraxonrasib, has shown promise in treating pancreatic cancer, doubling patient survival rates. Presented at the American Society of Clinical Oncology (ASCO) 2026 conference, the drug's clinical trial results were highly anticipated and met expectations. Pancreatic cancer is one of the deadliest forms of cancer, and this development represents a significant advancement in its treatment.


With a significance score of 6.6, this news ranks in the top 0.1% of today's 33867 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: